NCT06471712已完成1 期
A Phase I Clinical Trial of 18F-LNC1007 Injection PET/CT in Healthy Volunteers and Light Tumor Burden Patients for Evaluating Its Pharmacokinetics, Biodistribution,Dosimetry and Safety
Yantai LNC Biotechnology Singapore PTE. LTD.1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2024年7月29日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Evaluate the safety of 18F-LNC1007 injection
研究概览
简要总结
This study is a single-arm, single-center trial aimed at evaluating the pharmacokinetics, bio-distribution, dosimetry, and safety of 18F-LNC1007 injection in healthy volunteers and light tumor burden cancer patients, as defined by <5 lesions on a conventional PET/CT done for clinical purposes and molecular imaging tumor volume of <10ml.
All participants must provide a signed consent form before enrolling in the trial.
For each participant, the study duration will be about 3 weeks including 2 weeks' screening, 1 week of scanning and safety follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Express willingness and ability to comply with all study procedures and restrictions.
- •Be healthy adult volunteers, or light tumour burden cancer patients, as defined by <5 lesions and MITV of <10ml on a PET/CT performed for clinical purposes. Eligibility includes adults of any gender.
- •Have a Body Mass Index (BMI) between 19-28 (inclusive).
- •Be capable of lying on the scanner for the duration of the PET/CT procedure, which is approximately one hour.
- •Subjects must have an adequate organ function before the administration of the 18F-LNC1007 (in the absence of blood transfusion, hematopoietic stimulating and hepatoprotective agents), as defined by:
- •White blood cell (WBC) count ≥ 3×109/L or absolute neutrophil count (ANC) > 1.5×109/L, platelets ≥ 100×109/L, hemoglobin (Hb) > 10.0g/dL
- •Serum albumin > 3.0 g/dL, total bilirubin < 1.5×ULN, alanine aminotransferase (ALT) < 3×ULN, aspartate aminotransferase (AST) < 3×ULN
- •Creatinine clearance ≥ 60 mL/min (calculated using the Cockcroft-Gault formula).
- •Provide informed signed consent.
- •All females of childbearing potential (defined as premenopausal or less than 2 years post-menopausal who have not undergone surgical sterilization) must undergo a blood pregnancy test during the screening period (within 7 days before the administration of the drug). The result of the pregnancy test must be negative.
排除标准
- •Contraindications to PET/CT scan, which include, but are not limited to, conditions like claustrophobia and pregnancy.
- •A medical history of epilepsy or seizures, excluding febrile convulsions during childhood.
- •Blood donation or experienced major blood loss (> 400 mL) within 3 months prior to the screening or during the study period.
- •For healthy volunteers: participants with a clinically significant disease or medical history as determined by the trial investigator. This includes, but is not limited to:
- •Conditions related to circulatory, respiratory, digestive, urinary, hematological, neurological, endocrine, and musculoskeletal systems.
- •History of mental disorders or any other disease with clinical significance.
- •History of major surgery or anticipated major surgery within 1 month prior to the screening or during the study period.
- •For healthy volunteers: medical comorbidities that may interfere with the absorption or metabolism of the investigational drug, limit the interpretation of the trial results, and/or are deemed clinically significant by the investigator.
- •For healthy volunteers: abnormal findings in physical examination, vital signs, laboratory tests, or 12-lead ECG during the screening period, considered clinically significant by the investigator (Baseline physical examination, laboratory tests, and 12-lead ECG can accept results from Day -7 to Day -1).
- •For healthy volunteers: use of any prescription drugs, over-the-counter drugs, or traditional herbal medicine within 14 days before administration.
- •Active and clinically significant bacterial, fungal, or viral infections, including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness (patients with treated HIV and hepatitis B or C could be included).
- •Insufficient venous access (two different venous accesses are required for the injection of the experimental drug and PK blood sampling).
- •Female participants who are pregnant (positive pregnancy test at screening) or lactating, or are of childbearing potential (premenopausal or less than 2 years post-menopausal and have not undergone surgical sterilization), who do not agree to use effective contraception (such as complete abstinence, condom use, IUD, etc.) during the trial (from the signing of the informed consent) and for one month after administration.
- •Male participants with plans for procreation or sperm donation during the trial (from the signing of the informed consent) and one month after administration or who do not wish to take effective contraceptive measures (such as complete abstinence, condom use, surgical sterilization, etc.).
- •Subjects with a history of allergies that the investigator believes could increase the trial risk.
- •Clinically significant abnormalities on electrocardiogram (ECG) at screening including QTcF > 470 ms, and subjects who cannot tolerate high volume load.
- •Subjects who have undergone radioactive drug imaging (other than 18F-FDG) or treatment within 7 days prior to screening.
- •Subjects who have participated in other clinical trials within the past 1 month before the screening visit.
- •Participation in clinical trials of radiopharmaceuticals within 1 year prior to screening.
- •History of long exposure to high-dose radiation.
- •Subjects with a history of drug or alcohol abuse within the past year or a long-term history of drug use.
- •For light tumor burden patients: concurrent anti-cancer treatment;
- •For light tumor burden patients: previous major surgeries or anticipated major surgery within 1 month prior to the screening or during the study period.
- •Other conditions that the investigator believes render the participant not suitable for participating in the trial.
研究组 & 干预措施
18F-LNC1007 Injection
Experimental
a single dose of 18F-LNC1007 Injection will be administered
干预措施: 18F-LNC1007 Injection (Drug)
结局指标
主要结局
Evaluate the safety of 18F-LNC1007 injection
时间窗: Through study completion, assessed up to 2 years
The safety assessments of this phase I trial are based on systemic safety evaluation. The frequency and severity of Treatment emergent adverse events (TEAE) will be classified according to Common Toxicity Criteria for Adverse Events 5.0. The seriousness and relationship of study treatment will be assessed.
次要结局
- Evaluate the image quality of 18F-LNC1007 injection(Through study completion, assessed up to 2 years)
- Evaluate the metabolites of 18F-LNC1007 injection(Through study completion, assessed up to 2 years)
- Evaluate total source organ counts of 18F-LNC1007 injection(Through study completion, assessed up to 2 years)
- Evaluate the radioactivity of 18F-LNC1007 injection(Through study completion, assessed up to 2 years)
- Evaluate the SUV values of 18F-LNC1007 Injection(Through study completion, assessed up to 2 years)
- Evaluate the effective dose of 18F-LNC1007 injection(Through study completion, assessed up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian ParticipantsCovid19NCT04988152Vir Biotechnology, Inc.48
已完成
1 期
The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy SubjectsPharmacokineticsNCT05517616Ascentage Pharma Group Inc.6
已完成
1 期
Clinical Study of 68Ga-LNC1007 Injection PET/CTHealthy VolunteersCancer PatientsNCT06463782Yantai LNC Biotechnology Singapore PTE. LTD.8
已完成
1 期
Phase 1 Clinical Trial of RHN-001 in Healthy Adult VolunteersSafetyTolerabilityPharmacokineticsNCT05847218RH Nanopharmaceuticals64
已完成
1 期
First-in-human Study of Orally Administered KT-621 in Healthy Adult ParticipantsHealthy Participants StudyNCT06673667Kymera Therapeutics, Inc.118